DUBLIN, Ireland – Prothena Corporation plc (NASDAQ:PRTA) announced today it will release its fourth quarter and full-year 2025 financial results after the U.S. Markets close on Thursday, February 19, 2026. A live audio conference call is scheduled for 4:30 PM Eastern Time that day, providing investors with an opportunity to hear management’s review of the company’s performance.
The call will be accessible via webcast on Prothena’s investor relations website, located in the Events and Presentations section at www.prothena.com. An archived replay of the webcast will be available on the same webpage for at least 90 days following the call.
Investors and other interested parties can also participate via telephone. Dial-in numbers are +1 (800) 715-9871 for those in the U.S. And Canada, and +1 (646) 307-1963 for international callers. The conference ID number is 1706941. A replay will be available starting shortly after the call concludes, accessible via +1 (800) 770-2030 (U.S. And Canada) or +1 (609) 800-9909 (international), also using conference ID 1706941, until February 26, 2026.
Prothena focuses on developing therapies for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. The company’s pipeline includes programs targeting Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS), among others. Prothena’s proprietary CYTOPE® technology is central to its approach, aiming to modulate intracellular disease pathways in both the brain and peripheral tissues.
The upcoming financial results will be closely watched by the biotechnology sector, particularly given the challenges inherent in developing treatments for complex neurological conditions. According to a recent report from Hootsuite, maintaining consistent branding across social media platforms – including X (formerly Twitter), where Prothena maintains a presence at @ProthenaCorp – is crucial for companies in the healthcare space, and investor communication is a key component of that strategy (Hootsuite, February 2026).
Although Prothena has not publicly indicated the specific details to be discussed during the call, analysts anticipate updates on the progress of its clinical trials and a review of the company’s financial position as it continues to invest in its research and development programs. The company’s investor relations contact, Mark Johnson, CFA, can be reached at IR@prothena.com or 650-837-8550 for further inquiries.
